NBY vs CTXR vs PAHC vs MCK

For growth investors, Phibro Animal Health Corporation (PAHC) is the stronger pick with 27.

4% revenue growth year-over-year, versus -6. 4% for NovaBay Pharmaceuticals, Inc. (NBY). McKesson Corporation (MCK) offers the better valuation at 29. 2x trailing P/E (16. 7x forward), making it the more compelling value choice. Analysts rate Phibro Animal Health Corporation (PAHC) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, McKesson Corporation (MCK) is the cheapest at 29.

2x versus Phibro Animal Health Corporation at 36. 3x. On forward P/E, Phibro Animal Health Corporation is actually cheaper at 13. 1x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: McKesson Corporation wins at 0. 43x versus Phibro Animal Health Corporation's 1. 75x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +286.

9%, compared to -99. 9% for NovaBay Pharmaceuticals, Inc. (NBY). Over 10 years, the gap is even starker: MCK returned +339. 0% versus NBY's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), McKesson Corporation (MCK) is the lower-risk stock at -0.

02β versus Citius Pharmaceuticals, Inc. 's 2. 63β — meaning CTXR is approximately -16163% more volatile than MCK relative to the S&P 500. On balance sheet safety, Citius Pharmaceuticals, Inc. (CTXR) carries a lower debt/equity ratio of 2% versus 3% for Phibro Animal Health Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Phibro Animal Health Corporation (PAHC) is pulling ahead at 27.

4% versus -6. 4% for NovaBay Pharmaceuticals, Inc. (NBY). On earnings-per-share growth, the picture is similar: Phibro Animal Health Corporation grew EPS 1883% year-over-year, compared to 14. 9% for McKesson Corporation. Over a 3-year CAGR, PAHC leads at 11. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Phibro Animal Health Corporation (PAHC) is the more profitable company, earning 3.

7% net margin versus -73. 8% for NovaBay Pharmaceuticals, Inc. — meaning it keeps 3. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PAHC leads at 8. 5% versus -59. 7% for NBY. At the gross margin level — before operating expenses — NBY leads at 66. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, McKesson Corporation (MCK) is the more undervalued stock at a PEG of 0. 43x versus Phibro Animal Health Corporation's 1. 75x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Phibro Animal Health Corporation (PAHC) trades at 13. 1x forward P/E versus 16. 7x for McKesson Corporation — 3. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MCK: 32. 2% to $994. 86.

In this comparison, PAHC (1.

1% yield), MCK (0. 4% yield) pay a dividend. NBY, CTXR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, McKesson Corporation (MCK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

02), +339. 0% 10Y return). NovaBay Pharmaceuticals, Inc. (NBY) carries a higher beta of 2. 51 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MCK: +339. 0%, NBY: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: NBY is a small-cap quality compounder stock; CTXR is a small-cap quality compounder stock; PAHC is a small-cap high-growth stock; MCK is a mid-cap high-growth stock. PAHC pays a dividend while NBY, CTXR, MCK do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.